Search

Your search keyword '"Bighin C"' showing total 36 results

Search Constraints

Start Over You searched for: Author "Bighin C" Remove constraint Author: "Bighin C" Publisher elsevier ltd Remove constraint Publisher: elsevier ltd
36 results on '"Bighin C"'

Search Results

1. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

3. 35P SNPs of aromatase gene (CYP19A1) and outcomes of patients with estrogen receptor-positive (ER+) early breast cancer (eBC) treated with aromatase inhibitors (AIs): A multicenter, prospective study

9. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score

12. 270P Defining clinico-pathological characteristics of HER2 positive metastatic breast cancer (MBC) patients experiencing radiologic complete response (rCR) in a nationwide real-world cohort

18. 261P Survival outcomes of triple-negative breast cancer (TNBC) patients in the pre-immunotherapy age: An analysis of Gruppo Italiano Mammella (GIM) 14 BIOMETA study with a focus on biological subtypes

19. 118O Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: A randomised, phase III trial of the Gruppo Italiano Mammella

21. 95TiP Gruppo Italiano Mammella (GIM) 10 – CONSENT: A phase III randomized study comparing concurrent versus sequential administration of adjuvant chemotherapy (CT) and aromatase inhibitors (AIs) in post-menopausal patients (pts) with hormone receptor-positive (HR+) early breast cancer (EBC)

23. C1* - Trends in the choice of first line treatment for hormone - responsive (HR+), human epidermal growth factor receptor - 2 negative (HER2-) metastatic breast cancer (MBC) patients (pts): results of a multicentric Italian observational study

30. F01* - Dose-dense adjuvant chemotherapy, treatment-induced amenorrhea and overall survival in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase 3 studies

32. 4* - Ovarian suppression with luteinizing hormone-releasing hormone agonists during chemotherapy as a strategy to preserve ovarian function and fertility in breast cancer patients: a systematic review and meta-analysis of randomized studies

Catalog

Books, media, physical & digital resources